ABT
Abbott Laboratories (NYSE: ABT) delivered strong comparable sales growth of 3.
Article Summary
HOLD- Abbott Laboratories (NYSE: ABT) delivered strong comparable sales growth of 3.7% and EPS of $1.15, beating expectations, driven by strong medical devices growth led by cardiovascular and electrophysiology products.
- Core lab diagnostics delivered 3% growth driven by US, Europe, and Latin America, while the Medical Devices segment delivered 8.5% growth, supported by cardiovascular devices and new catheter launches.
- Diagnostics declined slightly due to lower respiratory virus testing demand and lower sales volumes in the Rapid and Molecular segment.
- Nutrition sales declined slightly, reflecting lower volumes and pricing actions, while EPD (Pharmaceuticals) grew 9% with double-digit growth in Latin America and Asia Pacific.
- Full-year EPS guidance reflects dilution from the Exact Sciences acquisition, though Abbott Laboratories expects $3 billion in incremental sales from Exact to be completed by end of 2026.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.7% | 25% | 35.0 ptsBelow Screener (5.7%) - Weak growth |
| EPS Growth Next 5Y ? | 9.9% | 25% | 20.0 ptsWeak (9.9%) - Low expectations |
| Target Price Upside ? | 32.6% | 20% | 85.0 ptsLarge Upside (32.6%) - Target: $127.00 vs Current: $95.80 |
| Gross Margin % ? | 52.7% | 15% | 80.0 ptsVery Healthy (52.7%) - High-quality margins |
| Drawdown from 52-Wk High ? | -31.1% | 15% | 80.0 ptsSolid Dip (-31.1%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABT
- Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
- It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
- The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
- In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.
- The company also provides cancer screening and diagnostic test products.
- The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
- Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.